Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation

[1]  Y. Song,et al.  Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer , 2017, Molecular carcinogenesis.

[2]  F. Sotgia,et al.  Cancer metabolism: a therapeutic perspective , 2017, Nature Reviews Clinical Oncology.

[3]  L. Holmberg,et al.  Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer , 2016, International journal of cancer.

[4]  S. Yeh,et al.  Targeting fatty acid synthase with ASC‐J9 suppresses proliferation and invasion of prostate cancer cells , 2016, Molecular carcinogenesis.

[5]  R. Kurumbail,et al.  Recent progress in the identification of adenosine monophosphate-activated protein kinase (AMPK) activators. , 2016, Bioorganic & medicinal chemistry letters.

[6]  Jessica Ward,et al.  Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy. , 2016, Journal of medicinal chemistry.

[7]  F. Ross,et al.  AMPK Causes Cell Cycle Arrest in LKB1-Deficient Cells via Activation of CAMKK2 , 2016, Molecular Cancer Research.

[8]  L. Butler,et al.  Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. , 2016, Endocrine-related cancer.

[9]  Xiu-Li Guo,et al.  Combinational strategies of metformin and chemotherapy in cancers , 2016, Cancer Chemotherapy and Pharmacology.

[10]  G. Nicolaes,et al.  Pharmacological Targeting of AMP-Activated Protein Kinase and Opportunities for Computer-Aided Drug Design. , 2016, Journal of medicinal chemistry.

[11]  A. Harris,et al.  Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments , 2016, Cancer & Metabolism.

[12]  S. Solomon,et al.  Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus☆,☆☆,☆☆☆ , 2016, The American journal of the medical sciences.

[13]  Yeji Kim,et al.  AMPK activators: mechanisms of action and physiological activities , 2016, Experimental & Molecular Medicine.

[14]  D. Hardie,et al.  AMP‐activated protein kinase: a cellular energy sensor that comes in 12 flavours , 2016, The FEBS journal.

[15]  N. Ahmad,et al.  Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer , 2016, Cell cycle.

[16]  D. Belsham,et al.  Glucose Alters Per2 Rhythmicity Independent of AMPK, Whereas AMPK Inhibitor Compound C Causes Profound Repression of Clock Genes and AgRP in mHypoE-37 Hypothalamic Neurons , 2016, PloS one.

[17]  Byung-Hyun Park,et al.  Compound C inhibits macrophage chemotaxis through an AMPK-independent mechanism. , 2016, Biochemical and biophysical research communications.

[18]  H. Yeh,et al.  Does Metformin Reduce Cancer Risks? Methodologic Considerations , 2016, Current Diabetes Reports.

[19]  Xiaoming Xie,et al.  AMPK and Cancer. , 2016, Experientia supplementum.

[20]  B. Viollet,et al.  Targeting AMPK: From Ancient Drugs to New Small-Molecule Activators. , 2016, Experientia supplementum.

[21]  Chao Wang,et al.  Low LKB1 Expression Results in Unfavorable Prognosis in Prostate Cancer Patients , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[22]  J. Gore,et al.  Metformin effects on biochemical recurrence and metabolic signaling in the prostate , 2015, The Prostate.

[23]  P. Ditonno,et al.  Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38 , 2015, Autophagy.

[24]  William H. Bisson,et al.  Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis? , 2015, Carcinogenesis.

[25]  A. Schally,et al.  Targeting the 5′-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer , 2015, Expert opinion on therapeutic targets.

[26]  Sandeep Rana,et al.  Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases. , 2015, Journal of medicinal chemistry.

[27]  Peiyuan Xu,et al.  LKB 1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway , 2015 .

[28]  Peiyuan Xu,et al.  LKB1 suppresses proliferation and invasion of prostate cancer through hedgehog signaling pathway. , 2014, International journal of clinical and experimental pathology.

[29]  G. MacLennan,et al.  Synergistic Simvastatin and Metformin Combination Chemotherapy for Osseous Metastatic Castration-Resistant Prostate Cancer , 2014, Molecular Cancer Therapeutics.

[30]  R. Kurumbail,et al.  Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite poles by different molecular mechanisms. , 2014, Structure.

[31]  Peng Lee,et al.  Lipid metabolism in prostate cancer. , 2014, American journal of clinical and experimental urology.

[32]  D. Neal,et al.  Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells , 2014, Oncotarget.

[33]  M. Loda,et al.  A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis , 2014, EMBO molecular medicine.

[34]  I. Nakano,et al.  The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent , 2014, Molecular Cancer Therapeutics.

[35]  A. Thompson,et al.  Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle , 2013, Clinical and Translational Oncology.

[36]  David Carling,et al.  Structural basis of AMPK regulation by small molecule activators , 2013, Nature Communications.

[37]  M. Loda,et al.  The fat side of prostate cancer. , 2013, Biochimica et biophysica acta.

[38]  Paula A. Oliveira,et al.  Estimation of rat mammary tumor volume using caliper and ultrasonography measurements , 2013, Lab Animal.

[39]  D. Hardie,et al.  AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells? , 2013, Biochemical Society transactions.

[40]  F. Nan,et al.  Development of Novel Alkene Oxindole Derivatives As Orally Efficacious AMP-Activated Protein Kinase Activators. , 2013, ACS medicinal chemistry letters.

[41]  T. Palmer,et al.  Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation , 2012, Expert opinion on investigational drugs.

[42]  A. Salminen,et al.  AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan , 2011, Journal of Molecular Medicine.

[43]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[44]  Anthony E. Klon,et al.  SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK) , 2010, Cancer biology & therapy.

[45]  C. Bertolotto,et al.  Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. , 2010, Cancer research.

[46]  Dong Wang,et al.  Highly Enantioselective and Organocatalytic α-Amination of 2-Oxindoles. , 2010 .

[47]  Mette Jensen,et al.  Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper , 2008, BMC Medical Imaging.

[48]  I. Ben-Sahra,et al.  The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.

[49]  J. Shreeve,et al.  Convenient fluorination of nitro and nitrile compounds with Selectfluor , 2005 .

[50]  Russell G. Jones,et al.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. , 2005, Molecular cell.

[51]  Chi‐Huey Wong,et al.  Selectfluor: mechanistic insight and applications. , 2004, Angewandte Chemie.

[52]  L. Overman,et al.  Enantioselective synthesis of (−)-idiospermuline , 2003 .

[53]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.